

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

1st October 2024

Company: Chordia Therapeutics, Inc
Representative: Chief Executive Officer Hiroshi Miyake
(Security Code: 190A TSE Growth Market)
Contact: Chief Financial Officer Kentaro Kume

**Announcement of Presentation on
Phase 1 Clinical Trial of CLK Inhibitor CTX-712
at the 86th Annual Meeting of the Japanese Society of Hematology**

Kanagawa Japan

1st October 2024 – Chordia Therapeutics Inc. (Head Office: Fujisawa City, Kanagawa Prefecture; President: Hiroshi Miyake) presented the results of an analysis of 14 patients with hematologic malignancies from a Japanese Phase 1 clinical trial of its CLK inhibitor, CTX-712, at the 86th Annual Meeting of the Japanese Society of Hematology being held at the Kyoto International Conference Center from October 11 to 13, 2024.

Abstract on our pipeline CLK inhibitor CTX-712 will be presented, the contents of which are as follows.

< Presentation on CTX-712, CLK inhibitor >

Abstract No	30064
Time	AM 8:20 – AM 9:15 11 th October 2024
Session No	Oral Session : O1-5A-2
Title	Efficacy and Genetic Analysis for A First-in-Human Phase I Study of CTX-712 in R/R AML/MDS

About CTX-712

CTX-712 is a first-in-class, selective, oral, small molecule inhibitor of CDC2-like kinase (CLK), a key regulator of the RNA splicing response that plays an important role in cell proliferation. A Phase 1/2 clinical trial in the U.S. is currently underway. Please visit: clinicaltrials.gov/ (NCT05732103) for more information on the U.S. Phase 1/2 clinical trial.

About Chordia Therapeutics

Chordia is a clinical stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan, engaged in the research and development of novel therapies for cancers.

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

ir@chorditherapeutics.com



Chordia's lead asset, CLK inhibitor CTX-712, is under Phase 1 clinical study in Japan and Phase 1/2 clinical study in the US. CTX-712 potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to CTX-712, Chordia is engaged in the research of several preclinical assets, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors. For more information, please contact our website <https://www.chorditherapeutics.com/en/>.